探究肝素寡糖靶向VEGF受体治疗乳腺癌的可能性【摘要】乳腺癌是乳腺上皮细胞在多种致癌因子的影响下发生增殖失控的现象。
手术治疗是目前乳腺癌患者的首选治疗方案，并配合以药物治疗，如化疗药物，内分泌类药物、靶向药物等。
血管内皮生长因子A(VEGF)是血管生成的主要介质。
此外，VEGF还直接作用于肿瘤细胞，促进肿瘤的生长和转移。
肿瘤细胞的生长与转移都依赖于肿瘤血管新生以及肿瘤细胞与内皮细胞的黏附。
肿瘤血管内皮细胞无论是生长还是分化都需要VEGF-A。
而肝素类化合物具有抗肿瘤活性能够抑制肿瘤细胞黏附于血小板或血管内皮，具有抗肿瘤活性。
因此本综述通过分析肝素寡糖与VEGF诱导的内皮细胞与乳腺癌细胞黏附的可能存在关系，探究其是否具有靶向VEGF受体而发挥抗肿瘤作用的潜力。
【Abstract】Breast cancer is a phenomenon of uncontrolled proliferation of mammary epithelial cells under the influence of various carcinogenic factors. Surgical treatment is currently the preferred treatment for breast cancer patients, combined with drug therapy, such as chemotherapy drugs, endocrine drugs, targeted drugs, etc. Vascular endothelial growth factor A(VEGF) is the major mediator of angiogenesis. In addition, VEGF also acts directly on tumor cells to promote tumor growth and metastasis. The growth and metastasis of tumor cells depend on tumor angiogenesis and the adhesion of tumor cells to endothelial cells. Both growth and differentiation of tumor vascular endothelial cells require VEGF-A. Heparin compounds have anti-tumor activity and can inhibit the adhesion of tumor cells to platelets or vascular endothelium, showing anti-tumor activity. Therefore, this review analyzed the possible relationship between heparin oligosaccharides and VEGF-induced adhesion of endothelial cells to breast cancer cells to explore whether heparin oligosaccharides have the potential to target VEGF receptors and play an anti-tumor role.【关键词】肝素寡糖VEGF A内皮细胞黏附 乳腺癌引言：据2018年国际癌症研究机构（IARC）的调查数据显示，乳腺癌在全球女性癌症发病率为24.1%，居女性癌症的首位，常被成为粉红杀手。
以上是毕业论文文献综述，课题毕业论文、任务书、外文翻译、程序设计、图纸设计等资料可联系客服协助查找。
